Empagliflozin
Indication: Type 2 Diabetes Mellitus
Interactive population PK and exposure-response simulator for empagliflozin (Jardiance) based on Baron et al. 2016. Explore effects of eGFR, age, BMI on PK and HbA1c lowering.
Drug Overview
Clinical Context
- Molecular Target
- SGLT2
- Drug Class
- SGLT2 inhibitor
- Therapeutic Area
- Type 2 Diabetes
- Indication
- Type 2 Diabetes Mellitus
- Route of Administration
- Oral
Model Information
- Model Type
- PopPK + Exposure-Response
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Empagliflozin allows you to explore concentration-time profiles under different dosing scenarios. The underlying PopPK + Exposure-Response model characterizes the pharmacokinetics of this sglt2 inhibitor following oral administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Empagliflozin PK simulator?
This is a free, interactive pharmacokinetic simulator for Empagliflozin used in Type 2 Diabetes Mellitus. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Empagliflozin belong to?
Empagliflozin is classified as a SGLT2 inhibitor that targets SGLT2. It is used in the Type 2 Diabetes therapeutic area.
What route of administration does this model simulate?
This simulator models Oral administration of Empagliflozin. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a PopPK + Exposure-Response model. Population PK models account for interindividual variability and covariate effects on drug exposure.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Ready to Simulate?
Launch the Empagliflozin simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community